Mallinckrodt, FTC And The Antitrust Risks Of Pipeline Acquisitions
Executive Summary
Acthar case could discourage firms looking to enhance franchises by acquiring drugs in development after FTC alleges firm purchased a would-be competitor to keep it off the US market. Is this something else we can blame on Martin Shkreli?
You may also be interested in...
Shkreli's Indictment May Help Industry Escape His Shadow
Having a pharma CEO arrested usually wouldn't be good news for industry – except it’s this guy.
Court Tosses Suit Over Lundbeck's Purchase Of Two Drugs Used In Premature Infants
Federal judge finds NeoProfen and Indocin IV are not in the same product market; FTC and Minnesota filed suit after Lundbeck raised the price of Indocin, then the only approved drug, by 1,300%.
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.